Prevalence, Risk Factors and Outcomes Associated with Acute Kidney Injury in Patients Hospitalized for COVID-19: A Comparative Study between Diabetic and Nondiabetic Patients
Table 3
Kidney involvement among study subjects, by diabetes status.
Variable
Total
Diabetes
Nondiabetes
value
AKI
58 (22.8)
36 (28.3)
22 (17.3)
0.04
Stage 1
22 (37.9)
9 (25.0)
13 (59.1)
0.03
Stage 2
21 (36.2)
15 (41.7)
6 (27.3)
Stage 3
15 (25.9)
12 (33.3)
3 (13.6)
Urine protein
Negative/trace
18 (45.0)
8 (30.8)
10 (71.4)
0.01
Positive
22 (55.0)
18 (69.2)
4 (28.6)
1 +
8 (36.4)
7 (38.9)
1 (25.0)
2+
4 (18.2)
2 (11.1)
2 (50.0)
≥3+
10 (45.4)
9 (50.0)
1 (25.0)
Hematuria
16 (38.1)
10 (38.5)
6 (37.5)
0.95
Urine specific gravity
1.024 (± 0.006)
1.023 (± 0.007)
1.025 (± 0.004)
0.59
Need for RRT after AKI development
8 (13.8)
7 (19.4)
1 (4.5)
0.07
Data are presented as mean (± SD), median (IQR), and (%). AKI: acute kidney injury; RRT: renal replacement therapy.
